• In early June 2026, OPKO Health amended its agreement with Nicoya Therapeutics, securing a 15% equity stake while preserving eligibility for up to US$115 million in potential RAYALDEE-related payments in Greater China and surrounding territories.
• This deeper Nicoya partnership adds an ownership position on top of royalties and milestones, tying OPKO Health more directly to RAYALDEE’s regional commercialization outcomes.
• Next, we’ll examine how OPKO’s new 15% Nicoya stake and reshaped RAYALDEE economics influence the company’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

OPKO Health Investment Narrative Recap

To own OPKO Health today, you need to believe that its mix of diagnostics, specialty pharma, and partnered programs can eventually translate into more sustainable economics despite ongoing losses. The amended Nicoya agreement strengthens OPKO’s exposure to RAYALDEE in Greater China, but it does not materially change the most immediate catalyst, which remains progress toward improving operating performance, nor does it remove the core risk around persistent unprofitability and cash burn.

Among recent announcements, OPKO’s reiterated 2026 revenue guidance of US$530 million to US$560 million is most relevant here. It frames the Nicoya stake as an incremental upside opportunity rather than a near term driver of the income statement, while the key near term test is whether OPKO can narrow its net losses from the US$225.7 million reported in 2025 and move its Diagnostics segment closer to breakeven.

Yet investors should also weigh the risk that recurring net losses and reliance on external funding could still pressure OPKO’s ability to support R&D and partnerships if...

OPKO Health’s narrative projects $608.2 million in revenue and $31.1 million in earnings by 2029.

Uncover how OPKO Health's forecasts yield a $3.40 fair value, a 136% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could reach about US$832 million by 2028 with earnings near US$43.9 million, which is a far more upbeat story than the baseline view of ongoing losses, and their assumptions about ModeX and oral peptides could look either more realistic or more stretched once the Nicoya RAYALDEE deal and OPKO’s recent results are fully reflected in updated forecasts.

Explore 3 other fair value estimates on OPKO Health - why the stock might be worth 11% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your OPKO Health research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• Our free OPKO Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate OPKO Health's overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.